Cited by 228Bioactive Compounds in PlantsPhytochemicals and Antioxidant ActivitiesFlavonoids in Medical Research

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis

Open access
Mulvihill, Erin E., Burke, Amy C., Huff, Murray W.·2016·Annual Review of Nutrition

Abstract

Citrus flavonoids are polyphenolic compounds with significant biological properties. This review summarizes recent advances in understanding the ability of citrus flavonoids to modulate lipid metabolism, other metabolic parameters related to the metabolic syndrome, and atherosclerosis. Citrus flavonoids, including naringenin, hesperitin, nobiletin, and tangeretin, have emerged as potential therapeutics for the treatment of metabolic dysregulation. Epidemiological studies reveal an association between the intake of citrus flavonoid–containing foods and a decreased incidence of cardiovascular disease. Studies in cell culture and animal models, as well as a limited number of clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of citrus flavonoids. In animal models, supplementation of rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through inhibition of hepatic fatty acid synthesis and increased fatty acid oxidation. Citrus flavonoids blunt the inflammatory response in metabolically important tissues including liver, adipose, kidney, and the aorta. The mechanisms underlying flavonoid-induced metabolic regulation have not been completely established, although several potential targets have been identified. In mouse models, citrus flavonoids show marked suppression of atherogenesis through improved metabolic parameters as well as through direct impact on the vessel wall. Recent studies support a role for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obesity, and atherosclerosis. Larger human studies examining dose, bioavailability, efficacy, and safety are required to promote the development of these promising therapeutic agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-nutr-071715-050718

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Research works printed but not linked: 2

  1. Roza JM, 2007, Altern. Ther. Health Med., 13, 44
  2. Xiong Y, 2010, Nan Fang Yi Ke Da Xue Xue Bao, 30, 321

Cited by

Sorted by citations

Items 101–200 of 227

Metadata

Authors
Mulvihill, E. E., Burke, A. C., & Huff, M. W.
Affiliations
Western University (CA)
Venue
Annual Review of Nutrition
Published
2016-07-17
Volume
36
Issue
1
Pages
275-299
ISSN
  • 0199-9885 (ISSN-L)
  • 1545-4312
OpenAlex
W2211999579
Cited by
228
References
100
Citations by year
2026: 20 · 2025: 15 · 2024: 24 · 2023: 19 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 25 · 2018: 17 · 2017: 9 · 2016: 4
FWCI
1.78
Type
journal article
Language
en
Open access
Locations
  • Annual Review of Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Heart and Stroke Foundation of Canada (G-14-0006179)
  • Canadian Institutes of Health Research (T-7007)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Bioactive Compounds in Plants
  • Health Sciences › Medicine › Biochemistry (medical) › Phytochemicals and Antioxidant Activities
  • Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords
citrus flavonoids, naringenin, hesperidin, nobiletin, tangeretin, lipoprotein metabolism, atherosclerosis, metabolic syndrome, dyslipidemia, insulin resistance, hepatic steatosis, hepatic fatty acid synthesis, fatty acid oxidation, anti-inflammatory activity, antihypertensive effect, cardiovascular disease prevention, obesity
MeSH terms
Animals, Anti-Inflammatory Agents, Non-Steroidal, Hypolipidemic Agents, Antioxidants, Citrus, Diabetes Mellitus, Type 2, Flavonoids, Humans, Hyperlipidemias, Insulin Resistance, Lipoproteins, Risk Factors, Anti-Obesity Agents, Dietary Supplements, Overweight, Atherosclerosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review